Originality & Strengths


 

  • Novelty and timeliness of technological advances (NGS with bioinformatics know-how for WES/WGS and single-cell RNASeq, novel in vitro models, in vitro and in vivo imaging, CRISPR-Cas genome editing, etc);

 

  • Proofs of concept have recently been reported demonstrating that VAs with an identified mutation are due to oncogenic drivers in endothelial cells and that molecular therapies inhibiting these pathways can increase quality of life of VA patients;

 

  • Multidisciplinary work (genetics, bioinformatics, cell biology, in vitro and in vivo modelling, imaging, flow –para-metering, transcriptomic profiling using RNAseq, signal transduction characterization, cfDNA analyses, pre-clinical testing);

 

  • International visibility of partners;

 

  • High applicability to the pharmaceutical field;

 

  • Answers an unmet medical need;

 

  • Engagement with Patient Organisation for the outreach;

 

  • Cover full cycle from patient – to bench and back to bedside;

 

  • Engagement of industrial partners with proprietary research technology and

 

  • Strengthening the existing and building new collaborations, giving high feasibility, but also novel ground-breaking research.